IRVINE, Calif. and HERSTAL, Belgium, Jan. 5, 2015 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
The presentation, "Epigenetic Biomarkers in Oncology", will highlight the development and commercialization of epigenetic diagnostic tests, several of which are now commercially available and used routinely in clinical practice.
All cancers show epigenetic changes. Measuring the epigenetic changes associated with specific genes can help guide physicians in the management of a patient's disease. With continued market adoption of the ConfirmMDx® for Prostate Cancer test, the inclusion of PredictMDx® for Glioblastoma into the NCCN guidelines, and the launch of Cologuard® for colon cancer by licensee Exact Sciences, there are now three successful diagnostic tests on the U.S. market using MDxHealth's epigenetic technology and biomarkers.
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
|Dr. Jan Groen, CEO||Mike Sinclair (Media)|
|US: +1 949 812 6979||UK: +44 20 7318 2955|
|BE: +32 4 364 20 70||Cell:+44 7968 022075|
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF version, click here http://hugin.info/137314/R/1883806/665487.pdf
Source: MdxHealth (TM)